Professor Charles Sande
Contact information
Podcast interview
Airway inflammation in early life

Chronic respiratory diseases disproportionately affects young adults in low income settings, particularly when they had been exposed to noxious substances from biomass smoke in early life. Using methods developed to understand airway inflammation caused by viral infections can help us understand the mechanisms underlying this pathology and better devise interventions.
Charles Sande
Associate Professor
My research focusses on pneumonia and other serious respiratory infections that affect infants and young children. Pneumonia remains a major killer, particularly in the developing world, where the healthcare infrastructure necessary for managing the most serious manifestations of the disease are inadequate. Our group is particularly interested in understanding the mechanisms of disease caused by respiratory infections such as respiratory syncytial virus (RSV) and Streptococcus pneumoniae. To gain a complete understanding of the mechanisms of disease pathology, we use a coordinated systems biology approach to examine in fine detail the interactions between the immune systems of sick children and the pathogens that cause pneumonia. We use a broad array of tools including mass spectrometry-based proteomics, protein microarrays, bacterial metagenomics and RNA-seq transcriptomics to understand host-pathogen interactions in the respiratory tract. Using these techniques we are gaining new insights into the breadth of the infant response to infection and how these responses may be leveraged in the development of effective interventions against pneumonia in the future.
Recent publications
-
Inflammation impairs post-hospital discharge growth among children hospitalised with acute illness in sub-Saharan Africa and south Asia
Preprint
Njunge J. et al, (2025)
-
The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access.
Journal article
Terstappen J. et al, (2024), Lancet Infect Dis, 24, e747 - e761
-
New SARS-CoV-2 Omicron Variant with Spike Protein Mutation Y451H, Kilifi, Kenya, March-May 2023.
Journal article
Mwanga MJ. et al, (2023), Emerg Infect Dis, 29, 2376 - 2379
-
Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults.
Journal article
Green C. et al, (2023), Clin Exp Immunol, 211, 269 - 279
-
A new Omicron lineage with Spike Y451H mutation that dominated a new COVID-19 wave in Kilifi, Coastal Kenya: March-May 2023
Preprint
Mwanga M. et al, (2023)